$RVMD$xbi@NatRevDrugDisc with an illuminating look at the question: Time to Peak Sales recently,
and think it’s constructive to view these dynamics against the would-be blockbuster du jour, $RVMD daraxonrasib.
@BioPharmaDive notes, from $rvmd earnings call, that
